Table 1 Patients demographics and characteristics
Patient | Age, gender | Diagnosis | Previous regimen | Cycles of BRAC | Response | Treatment after BRAC |
|---|---|---|---|---|---|---|
1 | 61, F | FL G1 | R-CHOP | 5 | PR | – |
2 | 53, F | FL G3b | R-CHOP | 4 | CR | auto HSCT |
3 | 71, F | FL G2 | R-THP-COP, R-IMVP-16/CBDCA, R-B, CHASER | 4 | CR | – |
4 | 66, M | FL G1 | R-THP-COP | 6 | PR | – |
5 | 63, F | FL G2 | R-CHOP | 4 | CR | – |
6 | 61, M | MCL | R-HyperCVAD/MA | 3 | CR | – |
7 | 67, M | MCL | R-CHOP, R-IMVP-16/CBDCA, CHASER, R-HyperCVAD/MA | 2 | NA | – |
8 | 57, M | FL G2 | R-CHOP, R-B | 3 | PR | allo HSCT |
9 | 69, F | FL G2 | R-THP-COP, R-B, R, R-Flu, GCD-R, Ibritumomab Tiuxetan | 3 | CR | – |
10 | 72, M | MCL | R-CHOP, R-B | 2 | NA | – |
11 | 72, M | FL G2 | R-CHOP, R-B | 4 | CR | – |
12 | 65, F | FL G1 | R-CHOP | 4 | CR | – |
13 | 69, F | MCL | R-CHOP | 6 | CR | – |